马萨诸塞州丹弗斯, Oct. 27, 2017 (GLOBE NEWSWIRE) -- 突破性心脏支架技术的领先提供商Abiomed, Inc. （纳斯达克代码：ABMD）今天宣布，2018财年第2季度收入1.328亿美元，较2017财年同期收入1.03亿美元增长29%。2018财年第2季度的GAAP净利润为2,450万美元或每股摊薄0.54美元，而去年同期的GAAP净利润为890万美元或每股摊薄0.20美元。
2018财年第2季度的财务和经营亮点包括：
- 来自Impella心脏泵的全球收入总计为1.274亿美元，较上个财年同期收入9,790万美元增长30%。来自Impella心脏泵的美国收入增长27%，为1.136亿美元，并且美国Impella患者使用率大幅增长33%。
- 在美国境外，Impella心脏泵的收入总计为1,380万美元，增长61%，其增长主要来自德国，该国业务收入较上个财年增长64%，患者人数刷新纪录。
- 在美国， Impella 2.5®心脏泵的安装点新增17间医院。这些医院首次购买Impella心脏泵，使客户安装点总数达到1,171个。Impella CP®心脏泵的客户安装点新增31间美国医院，使得Impella CP安装点的总数达到1,093个。Impella 5.0®心脏泵的客户安装点新增12间美国医院，Impella 5.0安装点总数达到484个。
- 另有44个安装点在本季度首次购买Impella RP®心脏泵，使该产品的安装点总数达到186个。
- 毛利率为84%，而上个财年则为83%。
- 营业收入为3,170万美元，营业利润率为24%，去年的营业收入为1,450万美元，营业利润率为14%。
- 受益于采用新会计准则，GAAP净利润为2,450万美元或每股摊薄收益0.54美元。根据新会计准则， 450万美元或每股摊薄0.10美元的员工股权激励相关的超额应税收入可以抵扣所得税支出。去年，采纳新会计准则之前的GAAP净利润为890万美元或每股摊薄0.20美元。
- 本公司产生3,010万美元的现金、现金等价物及有价证券，截至2017年9月30日的总额为3.192亿美元，而2017年6月30日则为2.891亿美元。公司目前没有负债。
- 2017年9月20日，Abiomed 的Impella RP心脏泵获得美国食品和药物管理局 (FDA) 的上市前批准 (PMA)。该项批准令Impella RP心脏泵成为经FDA批准的唯一经皮配置的临时心室支持装置，可安全有效地用于治疗右心衰竭。
- 在今天的另一份新闻稿中，Abiomed宣布日本有首名患者接受Impella®心脏泵的治疗。Impella 2.5和Impella 5.0心脏泵获许可用于治疗耐药性的急性心脏衰竭，且是日本医药品医疗机器综合机构 (Pharmaceuticals and Medical Devices Agency / PMDA) 批准的第一个及唯一一个经皮配置的临时心室支持装置。
Abiomed董事长、总裁兼首席执行官Michael R. Minogue表示，“本季度，我们在帮助美国和德国的患者方面刷新了记录。此外，我们继续看到我们的教育和培训举措取得了更好的临床结果。在我们推进护理标准、建立心脏复原领域的时候，团队能够持续调整和执行，这让我感到非常自豪。”
2018财年展望
本公司将其2018财年收入指引的下限上调500万美元，新范围为5.65亿美元至5.75亿美元，较去年的收入增长27%至29%。之前的指引为5.55亿美元至5.75亿美元，较去年增长25%至29%。本公司还上调本财年GAAP营业利润率的预报，从22%至24%调升至23%至25%。
电话会议
公司将于2017年10月26日星期四美国东部夏令时间早上8:00举行电话会议，以讨论业绩。董事长、总裁兼首席执行官Michael R. Minogue、前首席财务官Robert L. Bowen将主持电话会议。
欲收听电话会议直播，请通过http://investor.abiomed.com打开网播或拨打(855) 212-2361，国际号码为(678) 809-1538。本次电话会议的重播将在2017年10月26日美国东部夏令时间上午11点至2017年10月29日美国东部夏令时间上午11点播送。重播电话号码为(855) 859-2056，国际号码为(404) 537-3406。重播访问码为95924236。
ABIOMED 标识、ABIOMED、Impella、Impella CP和Impella RP等为Abiomed, Inc.在美国和某些外国注册的商标。Impella 2.5、Impella 5.0、Impella LD和Recovering Hearts、Saving Lives为Abiomed, Inc.的商标。
关于ABIOMED
Abiomed, Inc. 总部设在马萨诸塞州的丹弗斯，是一家提供循环支持的医疗器械的领先提供商。我们的产品用于改善血液流动及／或执行心脏的泵血功能，使心脏获得休息。欲了解更多信息，请访问网站：www.abiomed.com。
前瞻性陈述
本新闻稿包含前瞻性陈述，包括关于Abiomed新旧产品的开发、本公司商业发展进展、未来机会以及预期监管审批结果的陈述。本公司的实际业绩可能与前瞻性陈述中所预计的业绩存在重大差异，其原因有多个，包括开发、测试及相关监管审批所存在的不确定性，包括未来可能的亏损、制造工艺复杂、质量要求高、依赖于有限的供货来源、竞争、技术变革、政府监管、诉讼事务、未来资本需求、后续融资的不确定性以及本公司在美国证券交易委员会报备的文件中详细描述的其他风险及挑战，该等文件包括最近以10-K表形式报备的年度报告以及以10-Q表形式报备的季度报告。该等陈述仅反映截至本新闻稿发布之日的情况，故提醒读者不要过度依赖任何前瞻性陈述。如为反映在本新闻稿发布之日后发生的事件或情况或反映意外事件之发生而对任何前瞻性陈述进行修正，本公司没有义务公开发布该等修正之结果。
| Abiomed, Inc. and Subsidiaries | |||||||||
| Consolidated Balance Sheets | |||||||||
| (Unaudited) | |||||||||
| (in thousands, except share data) | |||||||||
| September 30, 2017 | March 31, 2017 | ||||||||
| ASSETS | |||||||||
| Current assets: | |||||||||
| Cash and cash equivalents | $ | 44,536 | $ | 39,040 | |||||
| Short-term marketable securities | 218,661 | 190,908 | |||||||
| Accounts receivable, net | 57,327 | 54,055 | |||||||
| Inventories | 40,632 | 34,931 | |||||||
| Prepaid expenses and other current assets | 9,014 | 8,024 | |||||||
| Total current assets | 370,170 | 326,958 | |||||||
| Long-term marketable securities | 55,954 | 47,143 | |||||||
| Property and equipment, net | 97,697 | 87,777 | |||||||
| Goodwill | 34,332 | 31,045 | |||||||
| In-process research and development | 16,016 | 14,482 | |||||||
| Long-term deferred tax assets, net | 106,798 | 34,723 | |||||||
| Other assets | 13,686 | 8,286 | |||||||
| Total assets | $ | 694,653 | $ | 550,414 | |||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | |||||||||
| Current liabilities: | |||||||||
| Accounts payable | $ | 16,667 | $ | 20,620 | |||||
| Accrued expenses | 35,256 | 37,703 | |||||||
| Deferred revenue | 10,584 | 10,495 | |||||||
| Current portion of capital lease obligation | 851 | 799 | |||||||
| Total current liabilities | 63,358 | 69,617 | |||||||
| Other long-term liabilities | 598 | 3,251 | |||||||
| Contingent consideration | 9,835 | 9,153 | |||||||
| Long-term deferred tax liabilities | 866 | 783 | |||||||
| Capital lease obligation, net of current portion | 15,110 | 15,539 | |||||||
| Total liabilities | 89,767 | 98,343 | |||||||
| Commitments and contingencies | |||||||||
| Stockholders' equity: | |||||||||
| Class B Preferred Stock, $.01 par value | — | — | |||||||
| Authorized - 1,000,000 shares; Issued and outstanding - none | |||||||||
| Common stock, $.01 par value | 442 | 437 | |||||||
| Authorized - 100,000,000 shares; Issued - 45,921,029 shares at September 30, 2017 and 45,249,281 shares at March 31, 2017 | |||||||||
| Outstanding - 44,200,784 shares at September 30, 2017 and 43,673,286 shares at March 31, 2017 | |||||||||
| Additional paid in capital | 592,081 | 565,962 | |||||||
| Retained earnings (accumulated deficit) | 90,164 | (46,959 | ) | ||||||
| Treasury stock at cost - 1,720,245 shares at September 30, 2017 and 1,575,995 shares at March 31, 2017 | (65,999 | ) | (46,763 | ) | |||||
| Accumulated other comprehensive loss | (11,802 | ) | (20,606 | ) | |||||
| Total stockholders' equity | 604,886 | 452,071 | |||||||
| Total liabilities and stockholders' equity | $ | 694,653 | $ | 550,414 | |||||
| Abiomed, Inc. and Subsidiaries | ||||||||||||||
| Consolidated Statements of Operations | ||||||||||||||
| (Unaudited) | ||||||||||||||
| (in thousands, except per share data) | ||||||||||||||
| Three Months Ended September 30, | Six Months Ended September 30, | |||||||||||||
| 2017 | 2016 | 2017 | 2016 | |||||||||||
| Revenue: | ||||||||||||||
| Product revenue | $ | 132,782 | $ | 102,928 | $ | 265,213 | $ | 205,917 | ||||||
| Funded research and development | 41 | 27 | 78 | 33 | ||||||||||
| 132,823 | 102,955 | 265,291 | 205,950 | |||||||||||
| Costs and expenses: | ||||||||||||||
| Cost of product revenue | 21,627 | 17,309 | 43,489 | 32,379 | ||||||||||
| Research and development | 19,390 | 18,052 | 36,321 | 33,712 | ||||||||||
| Selling, general and administrative | 60,080 | 53,086 | 120,677 | 104,118 | ||||||||||
| 101,097 | 88,447 | 200,487 | 170,209 | |||||||||||
| Income from operations | 31,726 | 14,508 | 64,804 | 35,741 | ||||||||||
| Other income: | ||||||||||||||
| Investment income, net | 781 | 342 | 1,416 | 611 | ||||||||||
| Other (expense) income, net | (23 | ) | (114 | ) | 56 | (191 | ) | |||||||
| 758 | 228 | 1,472 | 420 | |||||||||||
| Income before income taxes | 32,484 | 14,736 | 66,276 | 36,161 | ||||||||||
| Income tax provision (1) | 7,981 | 5,861 | 4,399 | 14,376 | ||||||||||
| Net income | $ | 24,503 | $ | 8,875 | $ | 61,877 | $ | 21,785 | ||||||
| Basic net income per share | $ | 0.56 | $ | 0.21 | $ | 1.41 | $ | 0.51 | ||||||
| Basic weighted average shares outstanding | 44,141 | 43,129 | 44,018 | 42,971 | ||||||||||
| Diluted net income per share (2) | $ | 0.54 | $ | 0.20 | $ | 1.36 | $ | 0.49 | ||||||
| Diluted weighted average shares outstanding | 45,698 | 44,580 | 45,655 | 44,493 | ||||||||||
| (1) Income tax provision includes the effect of the following item: | ||||||||||||||
| Excess tax benefits related to stock-based compensation awards * | $ | 4,434 | $ | — | $ | 21,276 | $ | — | ||||||
| (2) Diluted net income per share includes the effect of the following item: | ||||||||||||||
| Excess tax benefits related to stock-based compensation awards * | $ | 0.10 | $ | — | $ | 0.47 | $ | — | ||||||
| * In the first quarter of fiscal 2018, the Company adopted Accounting Standards Update No. 2016-09, Improvements to Employee Share-Based Payment Accounting, which requires that all excess tax benefits and tax deficiencies related share-based compensation arrangements be recognized as income tax benefit or expense, instead of in stockholders' equity as previous guidance required. | ||||||||||||||
欲了解更多信息，请联系：
Ingrid Goldberg
投资者关系部总监
978-646-1590
ir@abiomed.com